

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 July 2021 (08.07.2021)



(10) International Publication Number
WO 2021/138485 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) A61P 35/00 (2006.01)
A61K 9/20 (2006.01) C07C 15/00 (2006.01)
A61K 31/00 (2006.01) A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2020/067560

(22) International Filing Date:

30 December 2020 (30.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/955,062 30 December 2019 (30.12.2019) US
62/955,073 30 December 2019 (30.12.2019) US
62/968,695 31 January 2020 (31.01.2020) US
62/968,724 31 January 2020 (31.01.2020) US

(71) Applicant: **DECIPHERA PHARMACEUTICALS, LLC** [US/US]; 200 Smith Street, Waltham, MA 02451 (US).

(72) Inventors: **KAUFMAN, Michael, D.**; 200 Smith Street, Waltham, MA 02451 (US). **BONE, Scott**; 1201 NW Wall Street, Suite 200, Bend, OR 97703 (US). **BLOOM, Corey**; 1201 NW Wall Street, Suite 200, Bend, OR 97703 (US). **JORDAN, Fred**; 1201 NW Wall Street, Suite 200, Bend, OR 97703 (US).

(74) Agent: **KAVANAUGH, Theresa, C.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th FL, Boston, MA 02210 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA



(57) Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR α kinases, and oncogenic forms thereof.

WO 2021/138485 A1